AMGEN INC (AMGN) vs JOHNSON & JOHNSON (JNJ)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | AMGN | JNJ |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $36.75B | $94.19B |
| Revenue growth (YoY) | ▲ 10.0% | ▲ 6.0% |
| Net income | $7.71B | $26.8B |
| Gross margin | 67.2% | 67.9% |
| Diluted EPS | $14.23 | $11.03 |
| Insider net (6 mo) | +15.3K sh • 5 sells • 0 buys | −40.8K sh • 7 sells • 0 buys |
| Institutional owners | 46 | 47 |
| Institutional value held | $113.58B | $294.77B |
| Next earnings (est.) | Nov 3, 2026 | Around Jan 20, 2027 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About AMGEN INC (AMGN)
Amgen Inc. is a global biotechnology company, incorporated in California in 1980 and reincorporated in Delaware in 1987, that discovers, develops, manufactures, and delivers innovative medicines targeting areas of high unmet medical need, operating as a… Read more →
About JOHNSON & JOHNSON (JNJ)
Johnson & Johnson, incorporated in New Jersey in 1887, is a global healthcare holding company with approximately 138,200 full-time-equivalent employees engaged in the research, development, manufacture, and sale of a broad range of healthcare products. Read more →
Source: SEC EDGAR.